Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging

Urology

Volumn 56, Issue 2, 2000, Pages 255-260

  Catalona, William J ^a   Southwick, Paula C ^b   Slawin, Kevin M ^c   Partin, Alan W ^d   Brawer, Michael K ^e   Flanigan, Robert C ^f   Patel, Anup ^g   Richie, Jerome P ^h   Walsh, Patrick C ^d   Scardino, Peter T ^c   Lange, Paul H ^e   Gasior, Gail H ^b   Loveland, Kathleen G ^b   Bray, Kurtis R ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hybritech Incorporated   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY; TECHNIQUE;

AGE FACTORS; AGED; AREA UNDER CURVE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0033916382     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00637-3     Document Type: Article

References (32)

1. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
2. Keetch D.W., Catalona W.J., Smith D.S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 151:1994;1571-1574.
3. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men establishment of age-specific reference ranges . JAMA. 270:1993;860-864.
4. Seaman E., Whang M., Olsson C.A., et al. PSA density (PSAD) role in patient evaluation and management . Urol Clin North Am. 20:1993;653-663.
5. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
6. Christensson A., Laurell C.B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 194:1990;755-763.
7. Lilja H., Christensson A., Dahlen U., et al. Prostate-specific antigen in human serum occurs predominantly in complex with alpha1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
8. Stenman U.H., Leinonen J., Alfthan H., et al. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer assay of the complex improves clinical sensitivity for cancer . Cancer Res. 51:1991;222-226.
9. Christensson A., Bjork T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol. 150:1993;100-105.
10. Smith D.S., Catalona W.J. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol. 152:1994;1163-1167.
11. Semjonow A., Brandt B., Oberpenning F., et al. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate. 7:(suppl):1996;3-16.
12. Arcangeli C.G., Shepherd D.L., Smith D.S., et al. Correlation of percent free PSA and pathologic features of prostatic carcinomas. J Urol. 155:(suppl):1996;415. (abstract).
13. Arcangeli C.G., Humphrey P.A., Smith D.S., et al. Percentage of free serum prostate-specific antigen as a predictor of pathological features of prostate cancer in a screening population. Urology. 51:1998;558-565.
14. Pannek J., Rittenhouse H.G., Chan D.W., et al. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol. 159:1998;1238-1242.
15. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease a prospective multicenter clinical trial . JAMA. 279:1998;1542-1547.
16. Southwick P.C., Catalona W.J., Partin A.W., et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen a prospective multicenter clinical trial . J Urol. 162:1999;1346-1351.
17. Epstein J.I., Walsh P.C., Carmichael M.J., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 271:1994;368-374.
18. Carter H.B., Sauvageot J., Walsh P.C., et al. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol. 157:1997;2206-2209.
19. Scheckowitz E.M., Resnick M.I. Imaging of the prostate benign prostatic hyperplasia . Urol Clin North Am. 22:1995;321-332.
20. Schroder F.H., Hermanek P., Denis L., et al. The TNM classification of prostate cancer. Prostate. 4:(suppl):1992;129-138.
21. Woodrum D.L., French C., Shamel L.B. Stability of free PSA in serum samples under a variety of sample collection and sample storage conditions. Urology. 48:(suppl):1996;33-39.
22. Woodrum D.L., York L. Two year stability of free and total PSA in frozen serum samples. Urology. 52:1998;247-251.
23. Woodrum D.L., French C.F., Hill T.M., et al. Analytical performance of the Tandem®-R free PSA immuno-assay measuring free prostate specific antigen. Clin Chem. 43:1997;1203-1208.
24. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination enhancement of specificity with free PSA measurements . JAMA. 277:1997;1452-1455.
25. Catalona W.J., Hudson M.A., Scardino P.T., et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer receiver operating characteristic curves . J Urol. 152:1994;2037-2042.
26. Lodding P., Aus G., Bergdahl S., et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/mL prostate specific antigen. J Urol. 159:1998;899-903.
27. Bangma C.H., Rietbergen J.B.W., Kranse R., et al. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol. 157:1997;2191-2196.
28. Morote J., Raventos C.X., Lorente J.A., et al. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4 1 and 10 ng/mL . J Urol. 158:1997;502-504.
29. Smith D.S., Catalona W.J., Keetch D.W. Comparison of percent free PSA and PSA density as methods to enhance the specificity of PSA screening. J Urol. 155:(suppl):1996;422A. (abstract).
30. Carter H.B., Partin A.W., Luderer A.A., et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology. 49:1997;379-384.
31. Elgamal A.A., Cornillie F.J., Van Poppel H.P., et al. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol. 156:1996;1042-1049.
32. Epstein J.I., Chan D.W., Sokoll L.J., et al. Nonpalpable stage T1c prostate cancer prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings . J Urol. 160:1998;2407-2411.